BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Disc Medicine (NASDAQ:IRON) and increased the price target from $70 to $80.
February 29, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman has reaffirmed an Outperform rating on Disc Medicine and raised the price target from $70 to $80.
The increase in price target by a reputable analyst like Evan Seigerman suggests a positive outlook on the stock's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100